The HHIPL2 Knockout HeLa Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HeLa human cervical adenocarcinoma cell line, designed to disrupt the HHIPL2 gene. This loss-of-function model enables systematic investigation of HHIPL2’s role as a negative regulator of the Hedgehog signaling pathway. The polyclonal format preserves a heterogeneous knockout background, offering a more comprehensive representation of gene disruption effects compared to single-cell clones, and is suitable for pooled functional screens or bulk biochemical analyses. The gene editing is achieved through CRISPR/Cas9-mediated gene disruption, delivering a population-level knockout of the target locus without requiring single-cell isolation.
The host HeLa cell line is a widely utilized human epithelial model originally isolated from an HPV18-positive cervical adenocarcinoma. As a continuous cell line with robust proliferation, HeLa serves as a foundational platform for cancer research, cell cycle studies, and signal transduction assays. Its epithelial origin retains key characteristics relevant to tumor biology, including responsiveness to paracrine signaling molecules. The well-characterized nature of HeLa cells facilitates reproducible experimental results and permits cross-laboratory comparisons, making them an ideal chassis for interrogating the Hedgehog pathway via targeted gene knockout.
HHIPL2 is a member of the Hedgehog-interacting protein (HHIP) family, functioning as a secreted antagonist that directly binds Hedgehog ligands??including Sonic Hedgehog (SHH), Indian Hedgehog (IHH), and Desert Hedgehog (DHH)??thereby sequestering them from the Patched 1 (PTCH1) receptor. This interaction blocks SMO activation and downstream GLI transcription factor-mediated gene expression. The mechanistic model positions HHIPL2 upstream of PTCH1 and SMO, with its inhibitory activity shaped by GLI transcription factors that regulate HHIPL2 expression, forming a negative feedback circuit. Downstream targets of hedgehog signaling influenced by HHIPL2 include GLI1, CCND1 (Cyclin D1), MYC, and PTCH1 itself, all of which are critical for cell proliferation and oncogenesis.
In HeLa cells, which natively exhibit functional Hedgehog signaling components, HHIPL2 knockout permits detailed dissection of ligand-dependent and ligand-independent pathway activation. The loss of HHIPL2 is predicted to relieve inhibition of SMO signaling, leading to increased GLI transcriptional activity and upregulation of proliferative targets such as CCND1 and MYC??events frequently observed in basal cell carcinoma and medulloblastoma. Thus, this engineered model recapitulates a key facet of aberrant Hedgehog pathway activation found in human cancers. Researchers can leverage it to study the specific contribution of ligand sequestration to signal attenuation in an epithelial carcinoma background, where Hedgehog paracrine interactions are often compromised.
This knockout product is suited for a broad range of experimental workflows, including functional validation of HHIPL2, drug target screening, and mechanistic pathway decryption. Representative assays that can be performed with these cells include Western blot analysis of GLI proteins, RT-qPCR quantification of hedgehog target genes such as GLI1 and PTCH1, dual-luciferase reporter assays for GLI transcriptional activity, co-immunoprecipitation studies to examine ligand-receptor interactions upon HHIPL2 loss, and cell proliferation assays to assess phenotypic consequences. For additional technical details, protocols, or bulk inquiries, please contact Ascent Research.
